New cholesterol-fighting drug slashes heart attack risk, but at a steep price

Traders are worried that Repatha isn’t effective enough to justify the drug’s hefty price tag of over $14,500 per year.

Source: Amgen’s cholesterol-fighting drug disappoints, shares drop

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s